Compare Progressive Corp (PGR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Revvity Inc — how do they compare? Progressive Corp trades at $217.75 (market cap $126.95B), while Revvity Inc trades at $154.6 (market cap $16.98B). The key difference: Progressive Corp is far larger — about 7.5× Revvity Inc's market cap, and Revvity Inc is trading nearer its 52-week high, Progressive Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Revvity Inc for 12 Days on average.
| PGR | RVTY | |
|---|---|---|
Market Cap | $126.95B | $16.98B |
Volume | 2,749,438 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $242.16 | $157.36 |
52-Week Low | $190.40 | $82.26 |
Typical Hold Time | 81 Days | 12 Days |
Enterprise Value | $135.16B | $19.30B |
Dividend Yield | 0.18% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $218.51, up 2.05% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with 12.85% net income margin and 34.94% ROE, supported by consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026 with EPS of $4.85 versus $4.64 expected, though Q1 2026 slightly missed. Analyst consensus price target is $222.23 with 38.1% buy ratings.
PGR presents a favorable risk-reward profile with upside to consensus targets, though near-term overbought RSI conditions warrant caution. The insurance giant's telematics advantage and underwriting discipline provide competitive moat, while intensifying auto insurance competition represents the primary business risk. Current valuation at 10.97 P/E appears reasonable given growth trajectory and profitability metrics.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
